Skip to main content
Premium Trial:

Request an Annual Quote

New Online Assay Shop Signs on Nanostream as Service Provider

NEW YORK (GenomeWeb News) — Assay Depot, a soon-to-be-launched online "marketplace for drug-discovery services," has signed up Nanostream as a service provider, the companies said today.
Assay Depot will allow customers to choose a particular assay, mail in test samples, and receive a data report "a few weeks later." The online shopping site will include "multiple service providers offering a wide range of drug-discovery services," the companies added.
Nanostream has developed assays for kinases, lipid-modifying enzymes, proteases, and cytochrome P450 enzymes.
“Bioassay support has increasingly become too labor-intensive and too time-consuming for drug discovery organizations, which has led researchers to outsource this costly function,” Nanostream COO Jonas Ekblom said in a statement.
Assay Depot offers "a virtual laboratory where researchers can conduct their drug-discovery programs," which streamlines the process for the customer and the service provider, he added.
Last week, Assay Depot said it raised $1.8 million in Series A financing, which it plans to use to launch its online service early next year.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.